Bloodborne biomolecular markers in prostate cancer development and progression.
Prostate cancer is notoriously difficult to treat, which makes its early detection a priority. Biomarkers have been used to diagnose and monitor prostate cancer for more than 50 years, and the discovery of the serum marker prostate-specific antigen (PSA) significantly altered the detection and management of prostate cancer. But imperfect correlation with cancer hinders the usefulness of PSA. The elucidation and validation of new biological markers of prostate cancer should aid detection, and improve the application of the available therapeutics.
Bok
Robert A
RA
Department of Medicine, Urologic Oncology Program, Comprehensive Cancer Center, University of California San Francisco, California 94143, USA.
Small
Eric J
EJ
D014408:Biomarkers, Tumor / Q000097:blood*; D002455:Cell Division; D018450:Disease Progression; D006133:Growth Substances / Q000097:blood; D006728:Hormones / Q000097:blood; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009389:Neovascularization, Pathologic; D011471:Prostatic Neoplasms / Q000097:blood* / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D012697:Serine Endopeptidases / Q000097:blood / Q000378:metabolism
D014408:Biomarkers, Tumor; D006133:Growth Substances; D006728:Hormones; D012697:Serine Endopeptidases